Literature DB >> 19021752

Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.

Michael J Devine1, Patrick A Lewis.   

Abstract

The last decade has seen clear links emerge between the genetic determinants and neuropathological hallmarks of parkinsonism and dementia, notably with the discovery of mutations in alpha-synuclein and tau. Following the description of mutations in LRRK2 linked to Parkinson's disease, characterized by variable pathology including either alpha-synuclein or tau deposition, it has been suggested that LRRK2 functions as an upstream regulator of Parkinson's disease pathogenesis. This minireview explores this model, in the context of our current understanding of the biochemistry of LRRK2, alpha-synuclein and tau.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19021752     DOI： 10.1111/j.1742-4658.2008.06707.x

Source DB:  PubMed          Journal:  FEBS J        ISSN： 1742-464X            Impact factor:   5.542


  18 in total

1.  Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Andrew Ferree; Katelyn Smith; Eugenio Barone; Marzia Perluigi; Raffaella Coccia; William Pierce; Jian Cai; Cesare Mancuso; Rachel Squillace; Manfred Wiengele; Isabella Dalle-Donne; Benjamin Wolozin; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-03-20       Impact factor: 8.401

Review 2.  Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.

Authors:  Zhenyu Yue; M Lenard Lachenmayer
Journal:  Mov Disord       Date:  2011-04-29       Impact factor: 10.338

3.  Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation.

Authors:  Christian Wider; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Neurodegener Dis       Date:  2010-03-03       Impact factor: 2.977

4.  Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.

Authors:  Todd L Edwards; William K Scott; Cherylyn Almonte; Amber Burt; Eric H Powell; Gary W Beecham; Liyong Wang; Stephan Züchner; Ioanna Konidari; Gaofeng Wang; Carlos Singer; Fatta Nahab; Burton Scott; Jeffrey M Stajich; Margaret Pericak-Vance; Jonathan Haines; Jeffery M Vance; Eden R Martin
Journal:  Ann Hum Genet       Date:  2010-01-08       Impact factor: 1.670

5.  Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease.

Authors:  Michael H Yan; Xinglong Wang; Xiongwei Zhu
Journal:  Free Radic Biol Med       Date:  2012-11-29       Impact factor: 7.376

6.  LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease.

Authors:  Z Gan-Or; A Bar-Shira; A Mirelman; T Gurevich; M Kedmi; N Giladi; A Orr-Urtreger
Journal:  Neurogenetics       Date:  2009-05-21       Impact factor: 2.660

Review 7.  Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Authors:  Soumya Ray; Min Liu
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

8.  Tau acts as an independent genetic risk factor in pathologically proven PD.

Authors:  Gavin Charlesworth; Sonia Gandhi; Jose M Bras; Roger A Barker; David J Burn; Patrick F Chinnery; Stephen M Gentleman; Rita Guerreiro; John Hardy; Janice L Holton; Andrew Lees; Karen Morrison; Una-Marie Sheerin; Nigel Williams; Huw Morris; Tamas Revesz; Nicholas W Wood
Journal:  Neurobiol Aging       Date:  2012-01-04       Impact factor: 4.673

Review 9.  Evidence for the Role of Mitochondrial DNA Release in the Inflammatory Response in Neurological Disorders.

Authors:  Gonzalo E Moya; Phillip D Rivera; Kristin E Dittenhafer-Reed
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

10.  LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.

Authors:  Patrícia Silva Guerreiro; Yue Huang; Amanda Gysbers; Danni Cheng; Wei Ping Gai; Tiago Fleming Outeiro; Glenda Margaret Halliday
Journal:  J Mol Med (Berl)       Date:  2012-11-27       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.